



| | |
|--------------|---|
| Title | The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab |
| Author(s) | Kaneshiro, Shoichi; Ebina, Kosuke; Hirao, Makoto et al. |
| Citation | Modern Rheumatology. 2017, 27(1), p. 42-49 |
| Version Type | AM |
| URL | https://hdl.handle.net/11094/93266 |
| rights | This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
| Note | |

The University of Osaka Institutional Knowledge Archive : OUKA

<https://ir.library.osaka-u.ac.jp/>

The University of Osaka

Original Article

Title:

The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab

Authors:

Shoichi Kaneshiro^{1,2)}, Kosuke Ebina²⁾, Makoto Hirao²⁾, Hideki Tsuboi³⁾, Masataka Nishikawa¹⁾, Akihide Nampei⁴⁾, Yoshio Nagayama³⁾, Koichiro Takahi⁵⁾, Takaaki Noguchi²⁾, Hajime Owaki¹⁾, Jun Hashimoto⁶⁾, Hideki Yoshikawa²⁾

Affiliations:

- 1) Department of Orthopaedic Surgery, Japan Community Healthcare Organization, Osaka Hospital, 4-2-78 Fukushima, Fukushima Ward, Osaka City, Osaka 553-0003, Japan
- 2) Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan
- 3) Department of Orthopaedic Surgery, Osaka Rosai Hospital, 1179-3 Nagasone-cho, Sakai 591-8025, Japan

1
2
3 19 4) Department of Orthopaedic Surgery, National Hospital Organization Osaka Minami Medical

4
5
6 20 Center, 2-1 Kidohigashi, Kawachinagano, Osaka 586-8521, Japan

7
8
9 21 5) Department of Orthopaedic Surgery, Toneyama National Hospital, 5-1-1 Toneyama,

10
11
12 22 Toyonaka, Osaka 560-8552, Japan

13
14
15 23 6) Department of Rheumatology, National Hospital Organization Osaka Minami Medical

16
17
18 24 Center, 2-1 Kidohigashi, Kawachinagano, Osaka 586-8521, Japan

19
20
21
22 25

23
24
25 26 ***Keywords (alphabetical order):***

26
27
28 27 Biologics, Inadequate response, Rheumatoid arthritis, Tacrolimus, Tocilizumab

29
30
31
32 28

33
34
35 29 ***Corresponding author:***

36
37
38 30 Kosuke Ebina, MD, PhD, Assistant Professor

39
40
41 31 Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine,

42
43
44 32 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan

45
46
47 33 Phone: +81-6-6879-3552; Fax: +81-6-6879-3559

48
49
50 34 E-mail: k-ebina@umin.ac.jp

51
52
53
54 35

55
56
57 36 ***This article contains 4 figures and 1 table.***

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

37

38 *No supports or benefits in any form have been received for this report.*

39

1
2
3 40 **Abstract**

4
5
6 41 Objectives

7
8
9 42 Tocilizumab (TCZ) shows good retention in patients with rheumatoid arthritis (RA), but no
10
11
12 43 previous reports demonstrated hopeful treatment options against inadequate response to TCZ.
13
14
15 44 Tacrolimus (TAC) has proved to show efficacy against inadequate response to tumor necrosis
16
17
18 45 factor alpha inhibitors, yet its add-on effects on TCZ remain unknown.
19
20
21

22 46 Methods

23
24
25 47 Twenty patients with RA (17 women, age 58.6 y, disease duration 12.1 y, prior TCZ duration 2.6
26
27
28 48 y, 18 intravenous [8 mg/kg/month] and 2 subcutaneous [324 mg/month] TCZ treatment,
29
30
31 49 methotrexate 6.1mg/week [70.0%]) who showed an inadequate response to TCZ (clinical
32
33
34 50 disease activity index [CDAI] ≥ 5.8 , 18 secondary nonresponders) were additionally treated
35
36
37 51 with TAC (1.1 mg/day), and enrolled in this 24-week, prospective study.
38
39
40

41 52 Results

42
43
44 53 Seventeen patients (85.0%) continued the treatment for 24 weeks. Statistically significant
45
46
47 54 decreases in outcome measures were as follows: disease activity score based on 28 joints with
48
49
50 55 C-reactive protein (DAS28-CRP) from 3.3 at baseline to 2.1 at week 24 ($P < 0.001$), CDAI from
51
52
53 56 17.7 to 7.6 ($P < 0.001$), and serum matrix metalloproteinase-3 levels from 232.8 to 66.2 ng/mL
54
55
56 57 ($P < 0.001$). 15 patients (75%) achieved low disease activity or remission (DAS28-CRP ≤ 2.7 or
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

58 CDAI \leq 10) at week 24.

59 Conclusions

60 Adding low-dose TAC to inadequate responders to TCZ may be a promising complementary

61 treatment option.

62

Introduction

Tocilizumab (TCZ) is a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody of the IgG1 subclass directed at the IL-6R α chain. It was originally developed in Japan and has been widely used for the treatment of rheumatoid arthritis (RA) [1, 2] in clinical settings since 2008 in Japan, 2009 in Europe, and 2010 in the USA. Recently, the European League against Rheumatism (EULAR) announced a 2013 update to the 2010 recommendations for the management of RA with synthetic and biological DMARDs, in which TCZ is essentially considered to be as efficacious and safe as tumor necrosis factor alpha (TNF- α) inhibitors and should be considered as a first-line biologic agent [3]. In addition, we have previously demonstrated that TCZ therapy is associated with reduced serum oxidative stress levels [4] and may also promote osteoblast differentiation in patients with RA [5].

The EULAR recommendations support the use of all biological agents in combination with methotrexate (MTX) [3]. In patients with MTX contraindications or intolerance, TCZ may be considered as part of the first-line treatment strategy with biological agents [3]. Among all biological agents, only TCZ has been demonstrated to be superior as a monotherapy over MTX or other conventional DMARDs [1, 6]. In addition, TCZ is also effective and safe either with or without low-dose MTX for patients with active RA who inadequately respond to DMARDs and/or TNF- α inhibitors [7]. Therefore, TCZ tends to be chosen for patients who cannot tolerate

1
2
3 81 MTX in real-world setting.
4
5

6 82 However, there are some patients who experience lack of efficacy or loss of efficacy with TCZ.
7
8

9 83 In such cases, the EULAR recommendations suggest changing TCZ to another biologic with
10
11

12 84 another mode of action or add-on therapy with conventional DMARDs [3]. To date, however,
13
14

15 85 we lack reliable evidence for choosing alternative treatments for individual patients with RA
16
17

18 86 who previously had an inadequate response to TCZ, and frequent changes of biologics may lead
19
20

21 87 to multiple biologic failures.
22
23

24 88 Tacrolimus (TAC) is an antibiotic that was isolated from the fungus *Streptomyces tsukubaensis*
25
26

27 89 in Japan in 1984. In 1993, TAC was approved as a rejection inhibitor, and it is the most widely
28
29

30 90 used immunosuppressive drug in the transplantation field globally. In 2005, it was also
31
32

33 91 approved for use in RA, and the clinical efficacy of TAC as a single agent in RA has been
34
35

36 92 reported [8, 9]. Moreover, the concomitant use of small doses of TAC has been shown to be
37
38

39 93 effective when DMARDs [10] and TNF- α inhibitors have resulted in insufficient effects or in
40
41

42 94 cases of secondary failure [11, 12]. Therefore, we hypothesized that adding TAC may be a
43
44

45 95 hopeful complementary therapy for patients with an inadequate response to TCZ and examined
46
47

48 96 the efficacy and safety in this 24-week, prospective study.
49
50

51 97
52
53
54
55
56
57
58
59
60
61
62
63
64
65

98 **Patients and methods**

99 All of the patients with RA included in this study fulfilled the 1987 classification criteria of the
100 American College of Rheumatology [13]. TCZ was infused every 4 weeks at a dose of 8 mg/kg
101 or subcutaneously injected every 2 weeks at a dose of 162 mg in accordance with drug labeling
102 and the TCZ therapy guidelines of the Japan College of Rheumatology (JCR) [14]. Twenty
103 patients who had an inadequate response to TCZ in four hospitals associated with the Osaka
104 University Graduate School of Medicine participated in this prospective study from January
105 2012 to April 2015. An inadequate response to TCZ was defined as having all of the following
106 conditions met: clinical disease activity index (CDAI) score > 2.8 [15, 16] when TAC was
107 started; both tender joint count and swollen joint count were the same or increased compared to
108 those at 4 to 8 weeks prior to TAC; and TCZ was used at same dose for at least 8 weeks prior to
109 TAC. The patients were treated with TAC combination without changing the dosage of TCZ.
110 Efficacy and safety were evaluated 8 weeks later, 16 weeks later, and 24 weeks later. This
111 observational study was conducted in accordance with the ethical standards of the Declaration
112 of Helsinki and approved by the ethical review boards of the Osaka University Graduate School
113 of Medicine (approval number, 11258) and informed consent was obtained from patients
114 included in the study.

Evaluation of the activity of RA

Efficacy and safety were assessed by comparing changes in tender joint count (TJC) 28, swollen joint count (SJC) 28, patient's global assessment of disease activity (Pt-GA, 100 mm), physician's global assessment of disease activity (Ph-GA, 100 mm), serum C-reactive protein (CRP), serum matrix metalloproteinase-3 (MMP-3), white blood cell (WBC) count, lymphocyte count, and functional assessments according to the modified Health Assessment Questionnaire (mHAQ) scores [17] over time. Disease activity was assessed by measures including: disease activity score on 28 joints (DAS28) alone and with CRP (DAS28-CRP) [19], and CDAI score. DAS28-CRP was divided into four categories: remission \leq (2.3), low disease activity (> 2.3 and ≤ 2.7), moderate disease activity (> 2.7 and ≤ 4.1), and high disease activity (> 4.1). CDAI was divided into four categories: remission (≤ 2.8), low disease activity (> 2.8 and ≤ 10), moderate disease activity (> 10 and ≤ 22), and high disease activity (> 22) [16]. Observation points were set to the following five time points: 4-8 weeks prior to the start of TAC, at the start of TAC, 8 weeks after the start of TAC (week 8), 16 weeks after the start of TAC (week 16), and 24 weeks after the start of TAC (week 24). Clinical responses were defined by EULAR response criteria [19] and also with the American College of Rheumatology (ACR) 20% improvement criteria [20]. Trough whole-blood TAC concentrations were monitored, and any adverse events during the follow-up period were also examined.

Statistical analysis

Longitudinal changes of each parameter before and after TAC administration for 24 weeks were examined by the Wilcoxon signed-rank test. Differences in variables between the DAS28-CRP moderate- or good-response group and the no-response group after 24 weeks of TAC administration were assessed by the Mann-Whitney U test or chi-square test. Statistical data are expressed as the mean \pm standard deviation (SD), and P values of < 0.05 were considered statistically significant. All statistical analyses were carried out with IBM SPSS version 19 software (IBM, Armonk, NY, USA).

Results

Demographic data and drug therapy

Twenty patients (17 women) had inadequate responses to TCZ (2 primary non-responders and 18 secondary non-responders), and were then treated with add-on low-dose TAC (0.5–2 mg/day). Eighteen patients were treated with intravenous TCZ infusion, and two were treated with subcutaneous TCZ injection (Table 1). Their mean age was 58.6 y (range, 40–73 y), and mean disease duration was 12.1 y (range, 1–25 y). Of all the patients, 80.0% were in Steinbrocker's stage III or IV, and 25.0% were in

functional class 3 or 4. Both the rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody were positive in 17 patients (85.0%). TCZ was introduced as the first biologic in 7 patients, and the remaining 13 were bio-switched. 5 patients were switched from infliximab (IFX) and etanercept (ETN), 2 patients from golimumab (GOL), and 1 patient from adalimumab (ADA). TAC was started at 2.6 years (0.3–5.1) after the initiation of TCZ. The mean dose and usage rates of combined MTX were 6.1 mg/week (0–16) and 70.0% at baseline, and 5.6 mg/week (0–16) and 65.0% at week 24. Likewise, those of PSL were 1.1 mg/day (0–6) and 30.0% at baseline, and 0.7 mg/day (0–5) and 20.0% at week 24, respectively. Only 2 patients (10.0%) received bucillamine (BUC) and 3 patients received salazosulfapyridine (SASP) at baseline. Three patients (15.0 %) were treated without any conventional DMARDs (MTX, BUC, and SASP). No significant changes in the mean dose and prescription rate of MTX, PSL, BUC, and SASP were observed throughout the study.

Retention rate and combined TAC dose

Among all of the patients, 17 (85.0%) continued the combination treatment until week 24. Two patients discontinued for lack of efficacy, and one for digestive symptoms. Mean daily dose of TAC was 1.1 mg/day (0.5–2.0) at baseline and 1.1 mg/day (0.5–2.0) at week 24, which wasn't significantly changed throughout the study.

Adverse effects

During the follow-up period, 1 patient developed leukopenia ($< 3500/\mu\text{L}$) and 3 patients developed lymphopenia ($< 1000/\mu\text{L}$), although no apparent signs of infection were observed.

Serious adverse events that required medical intervention were not observed during the follow-up period.

Efficacy

Figs. 1, 2, and 3 show changes in clinical variables. The graphs include the data at 4-8 weeks prior to TAC initiation as representative data before an inadequate response to TCZ. The mean scores of DAS28-CRP were 2.6 ± 0.8 at 4–8 weeks prior to the start of TAC, 3.3 ± 0.8 at start of TAC, 2.4 ± 0.7 at week 8, 2.4 ± 0.9 at week 16, and 2.1 ± 0.6 at week 24 (Fig. 1a); the mean scores of CDAI were 11.5 ± 7.8 , 17.7 ± 7.6 , 9.6 ± 4.6 , 8.9 ± 7.3 , and 7.6 ± 4.4 , for the same periods, respectively (Fig. 1b). The mean serum MMP-3 level was 175.1 ± 203.4 ng/mL, 232.8 ± 241.2 ng/mL, 85.6 ± 70.3 ng/mL, 82.0 ± 98.2 ng/mL, and 66.2 ± 39.7 ng/mL, for the same periods, respectively (Fig. 1c). The mean serum CRP level was 0.16 ± 0.46 mg/dL, 0.27 ± 0.73 mg/dL, 0.05 ± 0.06 mg/dL and 0.05 ± 0.08 mg/dL, 0.05 ± 0.06 mg/dL, for the same periods, respectively (Fig. 1d). All scores were significantly improved from 8 weeks after TAC treatment. The mean serum RF level was 154.5 ± 192.5 at baseline and 173.4 ± 252.0 at week 24, which

1
2
3 190 didn't show significant change throughout the study.
4
5

6 191 The mean SJC was 3.3 ± 3.8 at 4–8 weeks prior to the start of TAC, 5.4 ± 4.0 at the start of TAC,
7
8
9 192 2.5 ± 2.7 at week 8, 1.6 ± 2.7 at week 16, and 1.4 ± 1.3 at week 24, respectively (Fig. 2a). The
10
11
12 193 mean TJC was 2.2 ± 3.1 , 2.7 ± 3.4 , 1.4 ± 2.3 , 2.2 ± 3.5 , 1.2 ± 2.3 , for the same periods,
13
14
15 194 respectively (Fig. 2b). The mean Pt-GA was 42.1 ± 19.7 , 54.8 ± 19.6 , 36.4 ± 20.4 , 35.0 ± 22.7 ,
16
17
18 195 29.5 ± 16.7 , for the same periods, respectively (Fig. 2c). The mean Ph-GA was 31.5 ± 13.5 , 45.4
19
20
21
22 196 ± 16.4 , 24.2 ± 9.7 , 19.6 ± 13.6 , 18.9 ± 11.2 , for the same periods, respectively (Fig. 2d). All of
23
24
25 197 which declined over time after the start of TAC.
26
27

28 198 No significant differences in changes in the WBC and lymphocyte counts were observed from
29
30
31 199 the initiation of TAC to after the initiation of TAC (Fig. 3a and b). The mean serum trough TAC
32
33
34 200 concentration (ng/ml) was 3.2 ± 3.0 at week 8, 3.7 ± 3.7 at week 16, and 3.2 ± 3.1 at week 24,
35
36
37 201 respectively (Fig. 3c). Only 10.0% (2/20) of patients obtained recommended reference value of
38
39
40
41 202 serum trough TAC concentration (5.0 - 20.0 ng/ml) at week 24. However, 83.3% (10/12) of
42
43
44 203 patients who showed lower serum trough TAC concentration than 5.0 ng/ml achieved low
45
46
47 204 disease activity ($CDAI \leq 10$) at week 24. Improvements were also seen in physical function.
48
49

50
51 205 The mean mHAQ score was 0.9 ± 0.4 at the start of TAC, which significantly improved to $0.5 \pm$
52
53
54 206 0.4 after 24 weeks of TAC therapy (Fig. 3d).
55
56

57 207 At week 24, 10 patients (50.0%) were in remission, five (25.0%) had low disease activity, and
58
59
60

two (10.0%) had moderate disease activity, except three (15.0%) who discontinued TAC based upon DAS28-CRP disease activity (Fig. 4a). In the same fashion, 14 (70.0%) had low disease activity, and three (15.0%) had moderate disease activity, except three patients (15.0%) who discontinued TAC based upon CDAI disease activity (Fig. 4b). At week 24, 12 of 19 (63.2%) patients achieved more than a moderate response according to the improvement criteria for response to treatment proposed by the EULAR (Fig. 4c). Percentages of patients who attained ACR 20 were 64.7%, 58.8%, and 70.6% at 8 weeks, 16 weeks, and 24 weeks, respectively (Fig. 4d).

Concerning the difference in the response to TAC between primary and secondary non-responders to TCZ, 100% (2/2) primary non-responders and 66.7% (12/18) secondary non-responders achieved low disease activity ($CDAI \leq 10$) at week 24. Likewise, difference in the response to TAC between bio-naïve and bio-switched patients, 57.1 % (4/7) bio-naïve and 76.9% (10/13) bio-switched patients achieved low disease activity ($CDAI \leq 10$) at week 24. There was no significant difference in the achievement ratio of low disease activity between the groups, respectively.

Discussion

Previously, Mori reported the efficacy of additional use of TAC after switching to TCZ in

226 patients who showed inadequate response to IFX, although the number of patients was only
 227 three, and also prior treatment was limited to IFX [21]. Recently, Ishida et al. reported the
 228 add-on effect of TAC in RA who showed inadequate response to biologics, although the ratio of
 229 TCZ was only 16.3%, and the clinical results were not distinguished between each biologics
 230 [22]. Taken together, this may be the first prospective report that focused on the safety and
 231 efficacy of additional treatment with TAC in a constant number of patients with RA, who
 232 showed an inadequate response to TCZ.

233 The efficacy might be explained by several mechanisms. Firstly, TAC forms a complex with
 234 FK506 binding protein 12 (FKBP-12), which in turn binds to calcineurin, blocking its activity.
 235 This process suppresses T-cell and B-cell activation, the production of antibodies by B cells
 236 [23], and also the production of pro-inflammatory cytokines such as TNF- α and IL-6 by
 237 activated T cells [24, 25]. This process may synergistically suppress the production of
 238 pro-inflammatory cytokines with TCZ and may also inhibit the production of autologous
 239 antibodies against biologics, which may lead to loss of efficacy [26]. Secondly, TAC also
 240 suppresses IL-6–induced inflammatory processes such as up-regulation of the receptor activator
 241 of NF- κ B ligand (RANKL) in fibroblast-like synoviocytes, by up-regulation of a suppressor of
 242 cytokine (SOCS3) signaling and consequent down-regulation of IL-6/Janus activated kinase
 243 (JAK2)/signal transducer and an activator of transcription-3 (STAT3) [27]. Moreover, TAC has

244 been proved to inhibit nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1
 245 (NFATc1) signaling and consequent osteoclasts differentiation [28]. TAC add-on therapy may
 246 enhance or restore the anti-inflammatory and anti-bone resorption effects of TCZ through these
 247 mechanisms. Thirdly, the long-term use of conventional DMARDs can result in a gradual
 248 decrease in their primary effects, such as “escape phenomenon” [29]. It has been reported that
 249 P-glycoprotein, which exports steroids and immunosuppressants from inside the target cells and
 250 mitigates their therapeutic effects, are induced when the transcription of multidrug resistance-1
 251 is induced [30]. By contrast, calcineurin inhibitors, such as TAC, bind to P-glycoprotein
 252 antagonistically, preventing drug export from target cells [30-32]. From these mechanisms,
 253 TAC may also restore the effects of other combined conventional DMARDs or glucocorticoids.
 254 Concerning the effective dose and serum concentration of TAC, the prescription dose of TAC
 255 was relatively small (1.1mg/day; range 0.5-2mg/day), and only 10.0% (2/20) of patients
 256 obtained the reference value of serum trough TAC concentration (5.0 - 20.0 ng/ml) at week 24.
 257 However, 83.3% (10/12) of patients who showed lower serum trough TAC concentration than
 258 5.0 ng/ml achieved low disease activity (CDAI \leq 10) at week 24. Taken together, lower serum
 259 TAC concentration than reference value may suffice for rescuing inadequate response to TCZ.
 260 Naniwa et al. [12] demonstrated the efficacy of additional TAC (1.5–2 mg/day) in patients with
 261 RA who were resistant to TNF- α inhibitors in combination with MTX. Recently, the efficacy

and safety of the combination of abatacept and TAC have been reported [33, 34]. Taken together, TAC seems to be a realistic therapeutic option in the treatment of active RA, especially for patients who cannot tolerate MTX and have an inadequate response to biologics.

There are several limitations to this study. First, this study lacks control group such as adding-on other DMARDs and is not a randomized comparative study. Second, leukopenia, lymphopenia, and consequent infection is major concerns when combining immunosuppressive agents, and the rates of these adverse effects might have been underestimated due to the small numbers of patients and short durations of follow-up. Third, precise mechanisms explaining how add-on TAC restores the efficacy of TCZ, even in low serum concentration, could not be specifically elucidated and should be evaluated in further studies. Fourth, whether this combination therapy consequently protects the joints from radiographic damage should be evaluated in large-cohort, longer-duration, randomized studies.

In conclusion, the results of this prospective study demonstrate that additional use of TAC can be considered as an effective complementary therapy for TCZ-refractory RA patients, especially those with intolerance to MTX.

Conflict of interest

No authors have any conflicts of interest.

Figure Legends

Figure 1. Changes in clinical variables for all patients

Mean values of (a) DAS28-CRP, (b) CDAI, (c) MMP-3, (d) CRP; *bars* indicate SD.

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$

IR, inadequate response; TCZ, tocilizumab; DAS28-CRP, disease activity score assessing 28

joints with CRP; CDAI, clinical disease activity index; MMP-3, matrix metalloproteinase-3;

CRP, C-reactive protein

Figure 2. Changes in clinical variables for all patients

Mean values of (a) SJC, (b) TJC, (c) Pt-GA, (d) Ph-GA; *bars* indicate SD.

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$

IR, inadequate response; TCZ, tocilizumab; SJC, swollen joint count; TJC, tender joint count;

Pt-GA, patient's global assessment of disease activity; Ph-GA, physician's global assessment of

disease activity

Figure 3. Changes in clinical variables for all patients

Mean values of (a) WBC count (cells/ μ l), (b) lymphocyte count (cells/ μ l), (c) serum trough

298 **TAC concentration (ng/ml)**, and (d) mHAQ; *bars* indicate SD.

299 * P < 0.05, ** P < 0.01, *** P < 0.001

300 IR, inadequate response; TCZ, tocilizumab; WBC, white blood cell; **TAC, tacrolimus**; mHAQ,
301 modified Health Assessment Questionnaire

302

303 **Figure 4.** Changes in distribution of disease activity and clinical responses

304 (a) Distribution of disease activity at the time of TAC initiation, 8 weeks, 16 weeks, and 24

305 weeks after TAC initiation; disease activity was defined using DAS28-CRP scores as follows:

306 remission, $\text{DAS28-CRP} \leq 2.3$; low disease activity, $2.3 < \text{DAS28-CRP} \leq 2.7$; moderate disease
307 activity, $2.7 < \text{DAS28-CRP} \leq 4.1$; high disease activity, $4.1 < \text{DAS28-CRP}$.

308 (b) Distribution of disease activity at the time of TAC initiation, 8 weeks, 16 weeks, and 24

309 weeks after TAC initiation; disease activity was defined using CDAI scores as follows:

310 remission, $\text{CDAI} \leq 2.8$; low disease activity, $2.8 < \text{CDAI} \leq 10$; moderate disease activity, $10 <$
311 $\text{CDAI} \leq 22$; high disease activity, $22 < \text{CDAI}$.

312 (c) Response to treatment according to the EULAR criteria at the time of TAC initiation, 8

313 weeks, 16 weeks, and 24 weeks after TAC initiation.

314 (d) Response to treatment according to the ACR 20% criteria at the time of TAC initiation, 8

315 weeks, 16 weeks, and 24 weeks after TAC initiation.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

316 TAC, tacrolimus; DAS28-CRP, disease activity score assessing 28 joints with CRP; CDAI,
317 clinical disease activity index; ACR20, American College of Rheumatology 20% improvement
318 criteria
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333

References

1. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T *et al.* Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. *Ann Rheum Dis.* 2007;66(9):1162-7.
2. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E *et al.* Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet.* 2008;371(9617):987-97.
3. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M *et al.* EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis.* 2014;73(3):492-509.
4. Hirao M, Yamasaki N, Oze H, Ebina K, Nampei A, Kawato Y *et al.* Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab. *Rheumatol Int.* 2012;32(12):4041-5.
5. Kaneshiro S, Ebina K, Shi K, Higuchi C, Hirao M, Okamoto M *et al.* IL-6 negatively

- regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways
- in vitro. *J Bone Miner Metab.* 2014;32(4):378-92.
6. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ *et al.* Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. *Ann Rheum Dis.* 2010;69(1):88-96.
7. Izumi K, Kaneko Y, Yasuoka H, Seta N, Kameda H, Kuwana M *et al.* Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: A single-center retrospective cohort study (KEIO-TCZ study) at week 52. *Mod Rheumatol.* 2014.
8. Kawai S, Hashimoto H, Kondo H, Murayama T, Kiuchi T, Abe T. Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. *J Rheumatol.* 2006;33(11):2153-61.
9. Aramaki T, Kawakami A, Iwamoto N, Fujikawa K, Kawashiri SY, Tamai M *et al.* Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables. *Mod Rheumatol.* 2009;19(6):652-6.
10. Suzuki K, Saito K, Tsujimura S, Nakayamada S, Yamaoka K, Sawamukai N *et al.*

- 1
2
3 370 Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by
4
5
6 371 P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. J Rheumatol.
7
8
9 372 2010;37(3):512-20.
10
11
12 373 11. Yokota K, Akiyama Y, Asanuma Y, Miyoshi F, Sato K, Mimura T. Efficacy of
13
14
15 374 tacrolimus in infliximab-refractory progressive rheumatoid arthritis. Rheumatol Int.
16
17
18 375 2009;29(4):459-61.
19
20
21 376 12. Naniwa T, Watanabe M, Banno S, Maeda T. Adding low dose tacrolimus in rheumatoid
22
23
24 377 arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies.
25
26
27 378 Rheumatol Int. 2009;29(11):1287-91.
28
29
30 379 13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS *et al.* The
31
32
33 380 American Rheumatism Association 1987 revised criteria for the classification of
34
35
36 381 rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.
37
38
39 382 14. Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K *et al.* Japan College of
40
41
42 383 Rheumatology 2009 guidelines for the use of tocilizumab, a humanized
43
44
45 384 anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod
46
47
48 385 Rheumatol. 2009;19(4):351-7.
49
50
51 386 15. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K *et al.* Acute phase
52
53
54 387 reactants add little to composite disease activity indices for rheumatoid arthritis:
55
56
57
58
59
60
61
62
63
64
65

- validation of a clinical activity score. *Arthritis Res Ther*. 2005;7(4):R796-806.
16. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. *Clin Exp Rheumatol*. 2005;23(5 Suppl 39):S100-8.
17. Pincus T, Summey JA, Soraci SA, Jr., Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. *Arthritis Rheum*. 1983;26(11):1346-53.
18. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum*. 1995;38(1):44-8.
19. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. *Arthritis Rheum*. 1996;39(1):34-40.
20. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C *et al*. American College of Rheumatology. Preliminary definition of improvement in rheumatoid

- 1
2
3 406 arthritis. *Arthritis Rheum.* 1995;38(6):727-35.
4
5
6 407 21. Mori S. Additional use of tacrolimus after switching to tocilizumab therapy in patients
7
8
9 408 with primary lack of efficacy of infliximab therapy for rheumatoid arthritis. *Mod*
10
11
12 409 *Rheumatol.* 2012;22(6):947-50.
13
14
15
16 410 22. Ishida K, Shiraki K, Yoshiyasu T. Evaluation of the safety and effectiveness of add-on
17
18
19 411 tacrolimus in patients with rheumatoid arthritis who failed to show an adequate
20
21
22 412 response to biological DMARDs: the interim results of a specific drug use-results
23
24
25 413 survey of tacrolimus. *Drugs R D.* 2015;15(4):307-17.
26
27
28
29 414 23. Miwa Y, Hosaka M, Ohtsuka K, Sato M, Takahashi R, Wakabayashi K *et al.* Depression
30
31
32 415 is improved when low-dose tacrolimus is given to rheumatoid arthritis patients showing
33
34
35 416 an inadequate response to biologic agents. *Mod Rheumatol.* 2013;23(5):920-4.
36
37
38 417 24. Sakuma S, Kato Y, Nishigaki F, Sasakawa T, Magari K, Miyata S *et al.* FK506 potently
39
40
41 418 inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human
42
43
44 419 peripheral blood mononuclear cells. *Br J Pharmacol.* 2000;130(7):1655-63.
45
46
47
48 420 25. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S. Comparison of anti-arthritic
49
50
51 421 properties of leflunomide with methotrexate and FK506: effect on T cell
52
53
54 422 activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced
55
56
57 423 arthritis. *Inflamm Res.* 2004;53(10):544-50.
58
59
60
61
62
63
64
65

- 424 26. Natsumeda M, Yamashita M, Takasugi K, Yamanaka R, Ezawa K, Ezawa K *et al.* Study
425 on the usefulness of adalimumab plus tacrolimus concomitant treatment given to
426 rheumatoid arthritis patients intolerant to methotrexate (in Japanese). J New Rem &
427 Clin. 2014;63(1):95-104.
- 428 27. Choe JY, Park KY, Park SH, Lee SI, Kim SK. Regulatory effect of calcineurin inhibitor,
429 tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through
430 JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes. Arthritis Res
431 Ther. 2013;15(1):R26.
- 432 28. Zawawi MS, Dharmapatni AA, Cantley MD, McHugh KP, Haynes DR, Crotti TN.
433 Regulation of ITAM adaptor molecules and their receptors by inhibition of
434 calcineurin-NFAT signalling during late stage osteoclast differentiation. Biochem
435 Biophys Res Commun. 2012;427(2):404-9.
- 436 29. Kawasaki Y, Moriyama M, Shibata K, Gomita Y. Effectiveness of methotrexate for the
437 escape by salazosulfapyridine (in Japanese). Yakugaku Zasshi. 2005;125(7):579-82.
- 438 30. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tsukada J, Kohno K *et al.*
439 Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in
440 lymphocytes. Genes Cells. 2004;9(12):1265-73.
- 441 31. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y. Clinical relevance of the

- 1
2
3 442 expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in
4
5
6 443 patients with systemic lupus erythematosus. *Arthritis Rheum.* 2005;52(6):1676-83.
7
8
9 444 32. Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y. Overcoming drug
10
11
12 445 resistance induced by P-glycoprotein on lymphocytes in patients with refractory
13
14
15 446 rheumatoid arthritis. *Ann Rheum Dis.* 2008;67(3):380-8.
16
17
18 447 33. Takahashi N, Fujibayashi T, Kida D, Hirano Y, Kato T, Kato D *et al.* Concomitant
19
20
21 448 methotrexate and tacrolimus augment the clinical response to abatacept in patients with
22
23
24 449 rheumatoid arthritis with a prior history of biological DMARD use. *Rheumatol Int.*
25
26
27 450 2015;35(10):1707-16.
28
29
30
31 451 34. Fujibayashi T, Takahashi N, Kida D, Kaneko A, Hirano Y, Fukaya N *et al.* Comparison
32
33
34 452 of efficacy and safety of tacrolimus and methotrexate in combination with abatacept in
35
36
37 453 patients with rheumatoid arthritis; a retrospective observational study in the TBC
38
39
40 454 Registry. *Mod Rheumatol.* 2015;25(6):825-30.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Table 1. Baseline characteristics of 20 patients

| | |
|---|---|
| Gender | 17 females, 3 males |
| Age (years) | 58.6 ± 9.3 (40-73) |
| Body weight (kg) | 53.3 ± 5.8 (42.8-63) |
| Steinbrocker' s stage (n) | Stage I 1 II 3 III 5 IV 11 |
| Steinbrocker' s functional class (n) | Class I 5 II 10 III 5 IV 0 |
| Duration of disease (years) | 12.1 ± 6.9 (1-25) |
| Duration of TCZ treatment (years) | 2.6 ± 1.6 (0.3-5.1) |
| Formulation of TCZ | i.v. 18, s.c. 2 |
| Type of TCZ failure (n) | 2 primary non-responders, 18 secondary non-responders |
| Prior use of biologics (n) | 7 bio-naïve, 13 bio-switched IFX(5) ETN (5) GOL (2) ADA (1) |
| MTX dose (mg/week), usage (% patients) | 6.1 ± 5.0 (0-16), 70.0% |
| PSL dose (mg/day), usage (% patients) | 1.1 ± 2.0 (0-6), 30.0% |
| BUC dose (mg/day), usage (% patients) | 22.2 ± 64.7 (0-200), 10.0% |
| SASP dose (mg/day), usage (% patients) | 147.1 ± 343.0 (0-1000), 15.0% |
| RF positivity, n/N (%) | 17/20, 85.0% |
| ACPA positivity, n/N (%) | 17/20, 85.0% |
| DAS28-CRP | 3.2 ± 0.8 (1.8-4.8) |
| SJC (swollen joint count), 0-28 | 4.8 ± 3.9 (1-16) |
| TJC (tender joint count), 0-28 | 2.6 ± 3.2 (0-14) |
| CRP (mg/dL) | 0.26 ± 0.71 (0.01-2.92) |
| Pt-GA (0-100 mm) | 54.9 ± 22.0 (10-95) |
| Ph-GA (0-100 mm) | 44.1 ± 18.2 (8-85) |
| CDAI | 17.2 ± 7.5 (5.8-38.5) |
| MMP-3 (ng/mL) | 215.1 ± 226.1 (24.6-771) |
| WBC count (cells/μl) | 6799 ± 3559 (2840-17700) |
| Lymphocyte count (cells/μl) | 1418 ± 608 (621.6-2534.4) |


2

3 Data are expressed as mean ± SD.


4 TCZ, tocilizumab; i.v., intravenous; s.c., subcutaneous; **IFX, infliximab; ETN, etanercept; GOL,**

5 golimumab; ADA, adalimumab; MTX, methotrexate; PSL, prednisolone; BUC, bucillamine;
6 SASP, salazosulfapyridine; RF, rheumatoid factor; ACPA, anti-cyclic citrullinated peptide
7 (anti-CCP) antibody; CRP, C-reactive protein; DAS28-CRP, disease activity score assessing 28
8 joints with CRP, SJC, swollen joint count; TJC, tender joint count; Pt-GA, patient's global
9 assessment of disease activity; Ph-GA, physician's global assessment of disease activity; CDAI,
10 clinical disease activity index; MMP-3, matrix metalloproteinase-3; WBC, white blood cell
11 $n/N (\%) = \text{number of patients with measurements} / \text{total number of patients} (\%)$
12


Figure
a




b



c




d




a

SJC (count)




b

TJC (count)




c

Pt-GA (100 mm)




d

Ph-GA (100 mm)




a

WBC (cells/ μ l)




b

Lymphocyte (cells/ μ l)




c

Trough TAC concentration (ng/ml)




d


mHAQ




a Distribution of DAS28-CRP disease activity



b Distribution of CDAI disease activity



c Response to treatment according to the EULAR criteria



d ACR 20 response rate

